000			04172nam a22003377a 4500
003			ZW-GwMSU
005			20210416113256.0
008			200608b ||||| |||| 00| 0 eng d
020			_a9780128040195
040			_bEnglish _cMSU _erda
050			_aQR187.3 _bIMM
245	0	0	_aImmunopotentiators in modern vaccines / _cedited by Virgil E. J. C. Schijns and Derek T. O'Hagan
250			_aSecond edition
264		1	_bAcademic Press, _c2017.
300			_a490 pages _billustrations
336			_2rdacontent _atext
337			_2rdamedia _aunmediated _bn
338			_2rdamedia carrier _avolume _bnc
504			_aIncludes bibliographical references and index.
505			_aUnravelling "the immunologist's dirty little secret" / Virgil E.J.C. Schijns -- Dendritic cells as targets and tools in vaccines / Imerio Capone, Paola Rizza, and Filippo Belardelli -- Host-derived molecules as adjuvants / Tom Barr, Jennifer Carlring, and Andrew W. Heath -- Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvants / Achal Pashine, Jeffrey B. Ulmer, and Nicholas M. Valiante -- CpG oligodeoxynucleotides as vaccine adjuvants / Michael J. McCluskie and Risini D. Weeratna -- Toll-like receptor 4 agonists as vaccine adjuvants / David H. Persing ... [et al.] -- Immunomodulatory adjuvants from Quillaja saponaria / Charlotte Read Kensil -- Microparticles as vaccine delivery systems / Derek T. O'Hagan -- MF59: a safe and potent adjuvant for human use / Audino Podda, Giuseppe Del Giudice, and Derek T. O'Hagan -- Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminium salt / Nathalie Garçon, Marcelle van Mechelen, and Martine Wettendorff -- Virosomes for vaccine delivery / Ian C. Metcalfe and Reinhard Glück -- The ISCOMATRIX adjuvant / Debbie Drane and Martin J. Pearse -- Mineral adjuvants / Erik B. Lindblad -- Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxin / Jan Holmgren ... [et al.] -- Transcutaneous immunization using the heat-labile enterotoxin of E. coli as an adjuvant / Richard T. Kenney and Gregory M. Glenn -- T cell adjuvants and novel strategies for their identification / Laurence Van Overvelt and Philippe Moingeon -- Vaccination to treat noninfectious diseases: surveying the opportunities / Stephen W. Martin and Martin F. Bachmann -- Clinical evaluation of adjuvants / Jakub K. Simon and Robert Edelman -- Regulatory considerations in the nonclinical safety assessment of adjuvanted preventive vaccines / Elizabeth M. Sutkowski and Marion F. Gruber
520			_aImmunopotentiators in Modern Vaccines, Second Edition, provides in-depth insights and overviews of the most successful adjuvants, those that have been included in licensed products, also covering the most promising technologies that have emerged in recent years. In contrast to existing books on the subject, the chapters here provide summaries of key data on the mechanisms of action of the individual vaccine adjuvants. In addition, the book covers key aspects of how the technologies might be further developed and what might be their limitations, while also giving an overview of what made the most advanced adjuvant technologies successful. Provides contributions from leading international authorities in the field; features immunopotentiators classified by function, with well-illustrated, informative figures presenting the interaction between the immunopotentiators and the host immune system; lists advantages and potential hurdles for achieving a practical application for each specific immunopotentiator; offers US FDA perspectives which highlight how future adjuvants will be approved for new generation vaccines.
650	2	2	_aImmunological adjuvants _vVaccine
650	2	2	_aImmune Response _vRegulation
650	2	2	_aVaccines _xImmunology
650	2	2	_aDrug delivery systems
650	2	2	_aAdjuvants, immunology
700	1		_aSchijns, Virgil E.J.C. _eEditor _eWageningen University, Wageningen, The Netherlands
700	1		_aO'Hagan, Derek T. _eEditor _eGSK Vaccines, Rockville, MD, United States
942			_2lcc _cB
999			_c152471 _d152471